MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc., a leading provider of advanced genomic sequencing and analytics to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies, today announced that the company’s Chief Scientific Officer (CSO), Dr. Richard Chen, will be speaking at the upcoming Neoantigen Summit, being held in Boston, MA from November 14-16, 2017.
The presentation entitled, “From Sample to Neoantigens for Vaccines: Key Challenges and Solutions” will cover topics including:
- cfDNA Neoantigens: dealing with tumor heterogeneity
- Improving neoantigen identification
- Elaborating tumor microenvironment (TME), immuno-modulators and vaccine response biomarkers
- Overcoming poor sample quality and quantity for NGS sequencing
- Addressing sequencing coverage gaps that can harbor neoantigens
- Validation and regulatory issues on the way to commercialization
Central to this presentation will be Personalis’ ACE ImmunoID™ Platform. The platform enables the comprehensive characterization of a tumor’s immuno-genomics including neoantigens, the tumor microenvironment, HLA, immuno-modulators and mechanisms of tumor escape to aid rational vaccine design.
“We are continuing to innovate to help our customers build safe, effective, and scalable personalized cancer vaccines. In this talk we will discuss how our ACE ImmunoID platform has been designed to overcome key challenges in personalized cancer vaccine development process starting from a tumor sample to neoantigen identification and rational vaccine design,” said Dr. Richard Chen, CSO at Personalis.
Personalis will also be exhibiting during the Neoantigen Summit. Representatives will be available to answer questions about the company’s neoantigen identification and immuno-genomics capabilities.
About Personalis, Inc.
Personalis, Inc. (www.personalis.com) is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. Personalis also provides DNA and RNA sequencing and data analysis of human genomes.
The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.
